Background: The National Eczema Association has received increasing numbers of patient inquiries regarding "steroid addiction syndrome," coinciding with the growing presence of social media dedicated to this topic. Although many of the side effects of topical corticosteroids (TCS) are addressed in guidelines, TCS addiction is not.

Objective: We sought to assess the current evidence regarding addiction/withdrawal.

Methods: We performed a systematic review of the current literature.

Results: Our initial search yielded 294 results with 34 studies meeting inclusion criteria. TCS withdrawal was reported mostly on the face and genital area (99.3%) of women (81.0%) primarily in the setting of long-term inappropriate use of potent TCS. Burning and stinging were the most frequently reported symptoms (65.5%) with erythema being the most common sign (92.3%). TCS withdrawal syndrome can be divided into papulopustular and erythematoedematous subtypes, with the latter presenting with more burning and edema.

Limitations: Low quality of evidence, variability in the extent of data, and the lack of studies with rigorous steroid addiction methodology are limitations.

Conclusions: TCS withdrawal is likely a distinct clinical adverse effect of TCS misuse. Patients and providers should be aware of its clinical presentation and risk factors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2014.11.024DOI Listing

Publication Analysis

Top Keywords

tcs withdrawal
12
systematic review
8
tcs
7
review topical
4
topical corticosteroid
4
withdrawal
4
corticosteroid withdrawal
4
withdrawal "steroid
4
"steroid addiction"
4
addiction" patients
4

Similar Publications

Pediatric Topical Steroid Withdrawal Syndrome: What Is Known, What Is Unknown.

Pediatr Dermatol

November 2024

Department of Dermatology, Northwestern University, Chicago, Illinois, USA.

Topical steroid withdrawal syndrome (TSW) is a debated condition marked by burning erythema, severe itching, and dry skin following the discontinuation of topical corticosteroids (TCS). This study reviewed reported pediatric TSW cases. With a total of 21 cases reported (inconsistent data provided), 60% (6/10) used TCS on the face; 69% (9/13) were associated with an escalation in potency of TCS and 75% (3/4) were the erythematoedematous variant.

View Article and Find Full Text PDF

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Cochrane Database Syst Rev

August 2024

National Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK.

Article Synopsis
  • Eczema is a widespread skin condition with no current prevention or cure, and existing treatments aim to control symptoms without clear consensus on their effectiveness and safety.
  • This study aims to compare and rank different topical anti-inflammatory treatments for eczema through a network meta-analysis of randomized controlled trials (RCTs).
  • The analysis focuses on various outcomes, including symptom relief, safety, quality of life, and withdrawal rates, while excluding certain types of eczema and treatments not related to topical anti-inflammatories.
View Article and Find Full Text PDF

Background: Topical corticosteroids (TCS) are first-line therapies for numerous skin conditions. Topical Steroid Withdrawal (TSW) is a controversial diagnosis advocated by patients with prolonged TCS exposure who report severe systemic reactions upon treatment cessation. However, to date there have been no systematic clinical or mechanistic studies to distinguish TSW from other eczematous disorders.

View Article and Find Full Text PDF

The term topical steroid withdrawal (TSW) refers to a condition widely discussed on social media, but rarely mentioned in the medical literature. It typically involves a patient with chronic eczema who abruptly discontinues topical corticosteroids (TCS) believing they are ineffective and damaging. Symptoms include an acute eruption, worse than the previous eczema, of painful erythema followed by oozing, crusting, desquamation and sometimes prolonged systemic weakness.

View Article and Find Full Text PDF

Topical corticosteroids (TCSs) are classified into four potencies: mild, moderate, potent and very potent. Confusion arises from the wide range of products available, none of which have the potency level printed on the tubes or packaging. An online survey of patients and carers of people with eczema showed that only 17% of 984 respondents knew how many potencies there are.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!